METHOD FOR IDENTIFYING A GROUP OF PEOPLE WITH AN INCREASED RISK OF DEVELOPING ALZHEIMER'S DISEASE Russian patent published in 2022 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to medicine and can be used to predict the risk of developing Alzheimer’s disease (AD) in individuals with mild cognitive decline (MCI). Markers of systemic inflammation are determined in the blood: C-reactive protein (CRP), interleukins IL-1β, IL-8, tumor necrosis factor TNFα. The severity of systemic inflammation is determined: 0 points if the level of all markers of systemic inflammation is lower than the reference values; 1 point if the level of 1 of the markers of systemic inflammation is higher than the reference values; 2 points if the level of 2 or more markers of systemic inflammation is higher than the reference values. With an assessment of 2 points, the presence of systemic inflammation is determined and after six months, the total immunoglobulin G (IgG) is determined in the blood. If the IgG level is below 10.0 g/l, an increased risk of developing Alzheimer's disease is determined in individuals with aMCI. If the IgG level is higher than 10.0 g / l, a low risk of developing Alzheimer’s disease is determined in individuals with aMCI.

EFFECT: method provides prediction of the development of Alzheimer’s disease in individuals with aMCI by determining the degree of immuno-inflammatory disorders by detecting the level of markers of humoral immunity, cytokines and chemokines, acute phase proteins in the patient’s blood.

1 cl, 2 dwg, 2 tbl, 4 ex